Explore more publications!
Health & Wellness Today New York
Got News to Share?

Health & Wellness Today New York: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on December 10, 2025

Norwegian Health-Tech Launches to Target Fibromyalgia, a $700B+ Productivity Crisis
December 10, 2025

Norwegian Health-Tech Launches to Target Fibromyalgia, a $700B+ Productivity Crisis

Indeterminate EIN Presswire
Data-Driven Norwegian App Launches to Bridge Clinical Gap for Fibromyalgia
December 10, 2025

Data-Driven Norwegian App Launches to Bridge Clinical Gap for Fibromyalgia

Indeterminate EIN Presswire
Deeply Transformative Mirror for the Mind Book NOW AVAILABLE on Amazon
December 10, 2025

Deeply Transformative Mirror for the Mind Book NOW AVAILABLE on Amazon

Indeterminate EIN Presswire
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Culture First - Inside Red Light Method's Unique Franchisee Selection Process
December 10, 2025

Culture First - Inside Red Light Method's Unique Franchisee Selection Process

Indeterminate EIN Presswire
Hexaview Unveils New Methodology: Prioritizing Understanding Before Modernization
December 10, 2025

Hexaview Unveils New Methodology: Prioritizing Understanding Before Modernization

Indeterminate EIN Presswire
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
December 10, 2025

NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO

Indeterminate GlobeNewswire
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
December 10, 2025

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Indeterminate GlobeNewswire
Clearmind Medicine Announces 1-for-40 Reverse Share Split
December 10, 2025

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Indeterminate GlobeNewswire
DLH Reports Fiscal 2025 Fourth Quarter Results
December 10, 2025

DLH Reports Fiscal 2025 Fourth Quarter Results

Indeterminate GlobeNewswire
Intuitive Announces Expanded Indications for da Vinci SP
December 10, 2025

Intuitive Announces Expanded Indications for da Vinci SP

Indeterminate GlobeNewswire
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
December 10, 2025

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

Indeterminate GlobeNewswire
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
December 10, 2025

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

Indeterminate GlobeNewswire
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 
December 10, 2025

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 

Indeterminate GlobeNewswire
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
December 10, 2025

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Indeterminate GlobeNewswire
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
December 10, 2025

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

Indeterminate GlobeNewswire
Alameda Health System wins equity award for breast cancer screening campaign
December 10, 2025

Alameda Health System wins equity award for breast cancer screening campaign

Indeterminate GlobeNewswire
Allsup Helps Individuals With Crohn’s Disease And Ulcerative Colitis Overcome Barriers To SSDI Benefits
December 10, 2025

Allsup Helps Individuals With Crohn’s Disease And Ulcerative Colitis Overcome Barriers To SSDI Benefits

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions